Clinical trials
NSCLC (Advanced Non-small Cell Lung Cancer) clinical trials
Below are recruiting nsclc (advanced non-small cell lung cancer) clinical trials, each written for real people, not researchers. We’re tracking 538 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06876675Enrolling by invitation
Lorlatinib and high cholesterol in ALK+ lung cancer
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
BeijingAges 18–80 - NCT06759857Enrolling by invitationPhase 3
New drug vs. afatinib for EGFR-mutant lung cancer
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
BeijingAges 1.5 years+ - NCT06370416Enrolling by invitationPhase 2
Preventing bone marrow suppression from chemo in advanced lung cancer
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Zhengzhou, HenanAges 18 years+ - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT04680377Recruiting
Using gut microbes to predict durvalumab side effects in lung cancer
This study looks at the microbiome (the tiny organisms in your gut) to try to predict who will get side effects from durvalumab after chemoradiation. If you join, your care team will use your microbiome results to help understand toxicity risk and improve future treatment planning.
Kansas City, KansasAges 18 years+ - NCT04144569RecruitingPhase 2
PD-1 plus pyrotinib for HER2-mutated lung cancer after chemo
This trial tests a combination treatment—PD-1 plus pyrotinib—in people with advanced lung cancer that has a specific HER2 “insertion” genetic change. It may help if your first standard chemotherapy did not work and you still have measurable tumors to track.
Changsha, HunanAges 18–75 - NCT03046316Recruiting
Local treatment for advanced lung cancer that hasn’t worsened
This trial looks at whether using focused treatments (like surgery or radiation to lung cancer spots) can help people with advanced non-small cell lung cancer whose disease has not progressed after first-line treatment. It’s meant for people who have limited metastatic spots and can safely undergo the local treatment.
Guangzhou, GuagndongAges 18 years+ - NCT06656598RecruitingPhase 2
Adjuvant treatment for elderly or unfit patients with stage III lung cancer
This trial tests whether adding an immunotherapy drug called cemiplimab to chemotherapy, followed by radiation, can help older or less fit patients with stage III lung cancer. The goal is to see if this combination improves outcomes compared to usual care.
AngersAges 18 years+ - NCT06607796RecruitingPhase 3
PTS injection for stage 4 lung cancer without gene mutations
This trial tests injecting a drug called PTS directly into lung tumors for people with stage 4 non-small cell lung cancer that doesn't have certain gene changes. It is for patients whose tumors have stayed stable after first-line treatment and are located in a small area of the outer lung.
Guangzhou, GuangdongAges 18–75 - NCT05857800Recruiting
Studying how lung tumor treatment affects the tumor environment
This trial studies how “before-surgery” (neoadjuvant) lung cancer treatments change the tumor environment by monitoring patients during care. It may help doctors better choose therapies and predict who benefits from treatment.
ShanghaiAges 18 years+ - NCT07603479RecruitingPhase 1
Testing JL19001 for Advanced Cancers and Lymphoma
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT07247227Recruiting
Sugemalimab plus chemotherapy for advanced lung cancer
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT04136535RecruitingPhase 2
Treating resistant lung cancer with chemo plus or minus an added drug
This Phase 2 study tests whether adding an extra targeted medicine (anlotinib) to standard chemotherapy (pemetrexed and carboplatin) can better control osimertinib-resistant lung cancer with an EGFR mutation. It’s for people whose lung cancer has already progressed after osimertinib, and it aims to shrink tumors and slow the disease.
Shenzhen, shenzhenAges 18–75 - NCT07109531RecruitingPhase 3
New drug combo for advanced lung cancer after TKI failure
This trial tests a combination of two experimental drugs (ASKC202 and limertinib) against standard chemotherapy for people with advanced non-small cell lung cancer that has a MET gene change and has stopped responding to earlier targeted therapy (EGFR-TKI). It aims to see if the new combination works better.
ShanghaiAges 18 years+ - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT06945705RecruitingPhase 2
Targeted therapy for EGFR-mutant lung cancer with brain spread
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
ZhengzhouAges 18 years+ - NCT05417321RecruitingPhase 1/Phase 2
Test of HB0036 for advanced cancers that ran out of options
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Lafayette, IndianaAges 18 years+ - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced cancers
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests an experimental drug (zongertinib) for people with advanced solid tumors that have certain changes in the HER2 gene. It's for those who have already tried at least one standard treatment and need more options.
Anchorage, AlaskaAges 18 years+ - NCT03803787RecruitingPhase 2
Inhaled steroid to prevent lung inflammation during cancer treatment
This trial tests whether breathing in steroid medicine before and during radiation can lower how often and how badly “radiation lung inflammation” (radiation pneumonitis) happens in people with lung cancer. If you qualify, it may help protect your lungs while you receive radiation with chemotherapy or targeted therapy.
Mexico CityAges 18–75
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nsclc (advanced non-small cell lung cancer)?
- Yes. Clin2 currently lists 538 recruiting nsclc (advanced non-small cell lung cancer) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nsclc (advanced non-small cell lung cancer) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nsclc (advanced non-small cell lung cancer) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.